Detailed Coverage

Dr Reddy's Q1 FY27 Earnings Update

Consolidated Revenue: ₹8,071 crore
Profit After Tax: ₹443 crore

Reader Takeaway: Revenue down due to product-specific issues, but underlying business growth offers optimism.

What just happened

Dr. Reddy's Laboratories reported its consolidated financial results for the first quarter of FY27. The company posted revenues of ₹8,071 crore, marking a 5.6% decrease compared to the same period last year. Profit After Tax (PAT) stood at ₹443 crore. The company also recorded an EBITDA margin of 12.5%, which was impacted by a significant provision.

Why this matters

The revenue decline was primarily driven by lower sales of the drug Lenalidomide. Additionally, a ₹240 crore provision for Semaglutide API-related challenges and increased operational costs affected profitability. While challenging, the company highlights that its base business, excluding Lenalidomide, continued to grow at double digits. The USFDA also completed an inspection with observations.

The backstory

Dr. Reddy's has been focusing on expanding its product portfolio and geographical reach. The company's performance is often influenced by the sales of key products and its ability to manage operational complexities and regulatory requirements. Recent quarters have seen varying impacts from product launches, generic competition, and R&D investments.

What changes now

The company has identified the root cause of the Semaglutide API operational issues and expects to resume commercial supplies by November, aiming to provide 6-7 million pens by March. Management believes that excluding the Semaglutide provision, the EBITDA margin would have been 15.4%, and targets a return to the 20% margin range soon. The USFDA observations at the Bachupally facility are deemed addressable.

Risks to watch

Key risks include the timely resumption of Semaglutide supplies and their commercial success, the successful resolution of USFDA observations, and potential impacts from ongoing geopolitical issues on freight and raw material costs. The decline in Lenalidomide sales also presents a challenge.

Peer comparison

Other pharmaceutical companies operating in similar therapeutic areas and markets also face challenges related to product-specific sales, API supply chain disruptions, and regulatory scrutiny. Performance varies based on product pipelines, R&D successes, and market access strategies.

Context metrics (time-bound)

For Q1 FY27, consolidated revenue was ₹8,071 crore (-5.6% YoY). R&D spend was ₹577 crore (-8.0% YoY), while SG&A spend increased by 12.0% to ₹2,882 crore. North America Generics revenue was US$236 million, showing a sequential growth of 19% despite a year-on-year decline.

What to track next

Investors will be watching the resumption of Semaglutide supplies in November, the company's ability to address USFDA observations, and the achievement of the targeted 20% EBITDA margin. Performance of the underlying base business will also be crucial.